Drugs / Hydrocholorthiazide
Hydrocholorthiazide
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01096667 Comparator | May 2010 → Feb 2011 | hypertensive disorder, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydrocholorthiazide | “Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days” NCT01096667 ↗ |
| Known as | HCTZ | “Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days” NCT01096667 ↗ |
| Known as | hydrochlorothiazide | “This study compared the blood pressure-lowering effect of ertugliflozin (1, 5, 25 mg), hydrochlorothiazide (HCTZ; 12.5 mg) and placebo in 194 patients” PMID 25951755 ↗ Jun 2015 |